Telaprevir's Efficacy Against Hepatitis C Trumps Standard Treatment
April 14, 2010
Mid-stage trial notes efficacy in investigational hepatitis C treatment
By Alaric DeArment
CORK, Ireland (Apr. 9) Patients with chronic genotype 1 hepatitis C fared better when given an investigational drug developed by Johnson & Johnson division Tibotec and Vertex Pharmaceuticals than when given the standard therapy, after they had failed previous treatments, according to results of a mid-stage trial published Thursday.
The results of the 453-patient, phase 2 “PROVE3” trial, published in the New England Journal of Medicine, found that regimens based on the drug telaprevir worked better than other drugs at keeping the virus undetectable in the bloodstream.
Continue reading this entire article:
Could Fermented Foods Help Hepatitis C?
Hepatitis C Ups Risk of Kidney Cancer